BioReliance (Merck)
Glasgow, UK · Rockville, MD
Hybrid — also manufactures internal programs
Compare AAV CDMOs in Europe
Compare AAV CDMOs in UK
Compare Lentiviral CDMOs in Europe
Compare Lentiviral CDMOs in UK
Compare Biologics CDMOs in Europe
Compare Biologics CDMOs in UK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-11-12
80.3
Signal Score
✓ FDA Inspections (6)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (10)
✓ HC GMP (49)
Quick Facts: BioReliance (Merck)
- Signal Score
- 80.3/100 (as of 2026-11-12)
- Quality Compliance
- 97.2/100 — Clean MHRA record: 10 compliant GMP certificates (no deductions)
- Headquarters
- Glasgow, UK · Rockville, MD
- Modalities
- AAV, Lentiviral, Biologics
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About BioReliance (Merck)
Hybrid developer + CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
97.2
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, MHRA GMDP
Clean MHRA record: 10 compliant GMP certificates (no deductions)
FDA Inspections6 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-05-13)
MHRA GMP Certificates10 on record
Most Recent HC OutcomeCompliant · 2026-03-27
HC Attribution49 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean MHRA record: 10 compliant GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Biologics
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
68.0
Parent company: Merck KGaA
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Merck KGaA
Financial assessment: 68.0/100
Capacity
63.0
3 manufacturing sites
Sites: Glasgow, UK, Rockville, MD, Stirling, UK
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
3 manufacturing sites
BioReliance (Merck) FDA Inspection History
2026-05
2026-01
2025-12
2024-11
2023-11
2023-08
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-05-13 |
Bioreliance Ltd.
Glasgow
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2026-01-29 |
BioReliance Corporation
Rockville, Maryland
Facility-linked
|
Bioresearch Monitoring | Yes | Voluntary Action Indicated (VAI) |
| 2025-12-05 |
Bioreliance Ltd.
Glasgow
Facility-linked
|
Vaccines and Allergenic Products | Not posted | Voluntary Action Indicated (VAI) |
| 2024-11-22 |
BioReliance Corporation
Rockville, Maryland
Facility-linked
|
Vaccines and Allergenic Products | Yes | Voluntary Action Indicated (VAI) |
| 2023-11-07 |
Bioreliance Ltd.
Glasgow
Facility-linked
|
Vaccines and Allergenic Products | Not posted | No Action Indicated (NAI) |
| 2023-08-04 |
BioReliance Corporation
Rockville, Maryland
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
BioReliance (Merck) FDA 483 Findings 3 observations · 2024-11-22 → 2026-01-29 ?
By subsystem
By severity
- 3 — Moderate: 2
- 2 — Minor: 1
- Repeat observations: 0
Most severe findings
-
Study director: unforeseen circumstances
"The study director failed to assure that unforeseen circumstances that might affect the quality and integrity of the nonclinical laboratory study were noted when they occurred and corrective action was taken and documented."
-
Investigations of discrepancies, failures
"There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed."
-
Study director: follow study protocol
"The study director failed to assure that the protocol, including any change, was approved and was followed."
BioReliance (Merck) MHRA GMP Compliance 10 certificates
2026-05
2026-05
2025-05
2025-05
2025-03
2025-03
2025-02
2025-02
2013-07
2012-07
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK API 22774 Insp GMP 22774/4473-0034 | BIORELIANCE LIMITED | GLASGOW G20 0XA | 2026-05-12 | COMPLIANT |
| UK MIA 22774 Insp GMP 22774/4473-0034[H] | BIORELIANCE LIMITED | GLASGOW G20 0XA | 2026-05-12 | COMPLIANT |
| UK GMP 22774 Insp GMP/IMP 22774/31007-0023 [H] | BIORELIANCE LIMITED | STIRLING FK9 4NF | 2025-05-02 | COMPLIANT |
| UK GMP 22774 Insp GMP/IMP 22774/31007-0023 [V] | BIORELIANCE LIMITED | STIRLING FK9 4NF | 2025-05-02 | COMPLIANT |
| UK GMP 22774 Insp GMP/IMP 22774/2062763-0012 [H] | BIORELIANCE LIMITED | PENICUIK EH26 0PZ | 2025-03-19 | COMPLIANT |
| UK GMP 22774 Insp GMP/IMP 22774/2062763-0012 [V] | BIORELIANCE LIMITED | PENICUIK EH26 0PZ | 2025-03-19 | COMPLIANT |
| UK MIA 22774 Insp GMP 13987/4473-0031[H] | BIORELIANCE LIMITED | GLASGOW G20 0XA | 2025-02-13 | COMPLIANT |
| UK API 22774 Insp GMP 13987/4473-0031 | BIORELIANCE LIMITED | GLASGOW G20 0XA | 2025-02-13 | COMPLIANT |
| UK GMP 18729 Insp GMP 18729/376405-0002[H] | BIORELIANCE CORPORATION | 20850-3349 | 2013-07-15 | COMPLIANT |
| UK MIA 22774 Insp GMP/IMP 22774/31007-0012[H] | BIORELIANCE LIMITED | STIRLING FK9 4NF | 2012-07-25 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Hiring Activity 16 open roles Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
16
open roles
5
in manufacturing, quality, PD/MSAT, engineering or regulatory (31%)
Trend from Nov 29, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 28, 2027.
Since Nov 19, 2026: 0 new postings, 882 taken down.
By function
By site
Rockville, Maryland, United States
profile site
· 4 QA/QC · 1 PD/MSAT · 8 other 13
· 4 QA/QC · 1 PD/MSAT · 8 other 13
Glasgow, Glasgow, United Kingdom
profile site
· 3 other 3
· 3 other 3
Latest postings
Senior QC Specialist
Quality (QA / QC) · Rockville, Maryland, United States
Quality Specialist 3 Systems Validation
Quality (QA / QC) · Rockville, Maryland, United States
Strategic Account Executive
Commercial, BD & client projects · Glasgow, Glasgow, United Kingdom
Chief of Staff BioReliance Testing Services
Other (finance, HR, IT, other) · Rockville, Maryland, United States
Field Marketing Manager
Commercial, BD & client projects · Glasgow, Glasgow, United Kingdom · posted Nov 17, 2026
Business Development Manager
Commercial, BD & client projects · Glasgow, Glasgow, United Kingdom · posted Nov 17, 2026
Associate Scientist 2
Process development & MSAT · Rockville, Maryland, United States
Business Development Manager Southwest
Commercial, BD & client projects · Rockville, Maryland, United States · posted Nov 10, 2026
Field Marketing Manager
Commercial, BD & client projects · Rockville, Maryland, United States
Business Development Manager Midwest
Commercial, BD & client projects · Rockville, Maryland, United States
Strategic Account Executive
Commercial, BD & client projects · Rockville, Maryland, United States · posted Nov 5, 2026
Quality Assurance Specialist 2
Quality (QA / QC) · Rockville, Maryland, United States · posted Nov 3, 2026
Coverage: read from the parent company's careers board and kept only postings at this business's sites (BioReliance testing sites (Rockville, Glasgow/Stirling); needs JSON-LD locations). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.emdgroup.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Frequently Asked Questions About BioReliance (Merck)
How many FDA inspections does BioReliance (Merck) have on record?
CDMO Signal tracks 6 FDA inspections for BioReliance (Merck), sourced from the FDA inspection database. See the full inspection history above.
Has BioReliance (Merck) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for BioReliance (Merck).
Does BioReliance (Merck) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 10 MHRA GMP certificates for BioReliance (Merck).
What is BioReliance (Merck)'s CDMO Signal Score?
BioReliance (Merck) has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating BioReliance (Merck) for a manufacturing program?
Use the free AI matchmaker to compare BioReliance (Merck) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
ProBioGen
Berlin, DE
Signal Score: 78.1
AAV, Lentiviral, Biologics
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Compare BioReliance (Merck) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.